• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Materials >Commercial Bone Grafts Claimed as an Alternative to Autografts: Current Trends for Clinical Applications in Orthopaedics
【2h】

Commercial Bone Grafts Claimed as an Alternative to Autografts: Current Trends for Clinical Applications in Orthopaedics

机译：商业骨移植物作为自体移植物的替代品：骨科临床应用的当前趋势

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the last twenty years, due to an increasing medical and market demand for orthopaedic implants, several grafting options have been developed. However, when alternative bone augmentation materials mimicking autografts are searched on the market, commercially available products may be grouped into three main categories: cellular bone matrices, growth factor enhanced bone grafts, and peptide enhanced xeno-hybrid bone grafts. Firstly, to obtain data for this review, the search engines Google and Bing were employed to acquire information from reports or website portfolios of important competitors in the global bone graft market. Secondly, bibliographic databases such as Medline/PubMed, Web of Science, and Scopus were also employed to analyse data from preclinical/clinical studies performed to evaluate the safety and efficacy of each product released on the market. Here, we discuss several products in terms of osteogenic/osteoinductive/osteoconductive properties, safety, efficacy, and side effects, as well as regulatory issues and costs. Although both positive and negative results were reported in clinical applications for each class of products, to date, peptide enhanced xeno-hybrid bone grafts may represent the best choice in terms of risk/benefit ratio. Nevertheless, more prospective and controlled studies are needed before approval for routine clinical use.
机译：在过去的二十年中，由于对骨科植入物的增加和市场需求，已经开发了几种接枝选择。然而，当在市场上搜索自体移植的替代骨增强材料时，市售产品可以分为三个主要类别：细胞骨矩阵，生长因子增强的骨移植物和肽增强的异杂交骨移植物。首先，为了获得本次审查的数据，搜索引擎谷歌和Bing受雇于从全球骨移植市场的重要竞争者的报告或网站投资组合中获取信息。其次，还采用了如Medline / PubMed，Scopus的书目数据库，分析了从进行的临床前/临床研究中进行数据，以评估市场上发布的每个产品的安全性和功效。在这里，我们在成骨/骨诱导/骨导电性能，安全性，疗效和副作用方面讨论了几种产品，以及监管问题和成本。迄今为止，迄今为止，迄今为止，迄今为止，迄今为止，迄今为止，肽增强的异杂交骨移植物可以代表风险/效益比的最佳选择。然而，在审批常规临床用途之前需要更多的前瞻性和受控研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号